Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valoctocogene Roxaparvovec (4E13 vg/kg) in Severe Hemophilia A
NCT03392974Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Mar 2018
- Primary completion
- May 2019
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 3 trial of valoctocogene roxaparvovec in hemophilia A, sponsored by BioMarin Pharmaceutical. Started Mar 2018; status: completed.
02
Drugs
valoctocogene roxaparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03392974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03392974.